Amount of business combination milestone payments.

No definition available.

Name:	syn_BusinessCombinationMilestonePayments
Namespace Prefix:	syn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of business combination milestone payments BLA approval .

+ References

No definition available.

+ Details

Name:	syn_BusinessCombinationMilestonePaymentsBlaApproval
Namespace Prefix:	syn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of business combination milestone payments first patient dosed.

+ References

No definition available.

+ Details

Name:	syn_BusinessCombinationMilestonePaymentsFirstPatientDosed
Namespace Prefix:	syn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of business combination milestone payments safe to proceed .

+ References

No definition available.

+ Details

Name:	syn_BusinessCombinationMilestonePaymentsSafeToProceed
Namespace Prefix:	syn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of cash payments existing liabilities.

+ References

No definition available.

+ Details

Name:	syn_CashPaymentsExistingLiabilities
Namespace Prefix:	syn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of finance the costs.

+ References

No definition available.

+ Details

Name:	syn_ClosingFinanceCosts
Namespace Prefix:	syn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of consideration for the purchase paid.

+ References

No definition available.

+ Details

Name:	syn_ConsiderationPurchasePaid
Namespace Prefix:	syn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of voting equity interests acquired at the acquisition date in the business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The compensation expense recognized during the period pertaining to the deferred compensation arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-SubTopic 10
-Section 30
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363

+ Details

Name:	us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum term of the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-SubTopic 10
-Section 55
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367

+ Details

Name:	us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_TitleOfIndividualAxis=syn_StevenAShallcrossMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=syn_VcnPrivateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=syn_GrifolsInnovationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=syn_NewTechnologiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_OtherFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_OtherSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Subsequent Events (Details) - USD ($)	Mar. 10, 2022	Jan. 03, 2022	Dec. 30, 2020
Steven A. Shallcross
Subsequent Event [Line Items]
Annual cash performance bonus			62.00%
Subsequent Event \| Steven A. Shallcross
Subsequent Event [Line Items]
Employment agreement term		3 years
Annual base salary		$ 585,000
Subsequent Event \| Steven A. Shallcross \| Maximum
Subsequent Event [Line Items]
Annual cash performance bonus		50.00%
Subsequent Event \| VCN Private [Member]
Subsequent Event [Line Items]
Consideration purchase paid	$ 4,700,000
Existing liabilities	2,400,000
Finance costs	425,000
Budgetary plan	27,800,000
Milestone payments	$ 12,000,000
Subsequent Event \| VCN Private [Member] \| Grifols Innovation
Subsequent Event [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	86.00%
Subsequent Event \| VCN Private [Member] \| New technologies
Subsequent Event [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	19.99%
Subsequent Event \| VCN Private [Member] \| Other First Indication [Member]
Subsequent Event [Line Items]
Milestone payments safe to proceed	$ 3,000,000
Milestone payments first patient dosed	3,250,000
Milestone payments	6,000,000
Milestone payments BLA approval	16,000,000
Subsequent Event \| VCN Private [Member] \| Other Second Indication
Subsequent Event [Line Items]
Milestone payments safe to proceed	2,750,000
Milestone payments first patient dosed	3,250,000
Milestone payments	8,000,000
Milestone payments BLA approval	$ 16,000,000